April Sales Reach 8.8 Billion Won, According to UBIST

"Clinical Value Recognized in Medical Practice"

JW Pharmaceutical announced on the 16th that its dyslipidemia treatment, Livarojet 2mg/10mg, ranked first in sales in the overall market for dual combination drugs (statin·ezetimibe) in April.


According to UBIST, a pharmaceutical market research firm, Livarojet 2mg/10mg recorded sales of 8.8 billion won and a market share of 6.59% in the overall market for dual combination drugs for dyslipidemia as of April, ranking first in sales. This figure represents an increase compared to December of last year, when sales reached 8.4 billion won (market share 6.32%).

JW Pharmaceutical Livalojet 2 and 10 mg. JW Pharmaceutical

JW Pharmaceutical Livalojet 2 and 10 mg. JW Pharmaceutical

View original image

Livarojet is the first improved dual combination drug in Korea that combines pitavastatin and ezetimibe, both active ingredients for the treatment of dyslipidemia. Pitavastatin inhibits cholesterol synthesis in the liver, while ezetimibe blocks cholesterol absorption in the small intestine, helping to reduce low-density lipoprotein cholesterol (LDL-C) levels.


The company believes these results reflect the LDL-C control efficacy and safety profile of pitavastatin, as well as the product competitiveness of the original combination therapy. Livarojet 2mg/10mg is a dosage that combines 2mg of pitavastatin and 10mg of ezetimibe, and is used as a combination treatment option for patients whose LDL-C is not sufficiently controlled with statin monotherapy alone.


Dyslipidemia is a chronic condition that requires long-term medication and continuous LDL-C management, making it important to choose a therapy that considers both efficacy and safety from the initial stage of treatment. As a pitavastatin-based combination drug, Livarojet is regarded as a treatment option for dyslipidemia patients, offering LDL-C lowering effects as well as a favorable safety profile regarding blood glucose elevation and muscle-related adverse reactions.



A representative from JW Pharmaceutical stated, "These results demonstrate the clinical value of Livarojet in medical practice, based on its LDL-C lowering effect and safety in terms of blood glucose and muscle-related events. We will continue to provide evidence and product information needed for patients requiring long-term LDL-C management from the early stage of treatment, as well as for those who also need to consider blood glucose control."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing